MedPath

Nebulized Tranexamic Acid in Sinus Surgery

Phase 3
Recruiting
Conditions
Bleeding Nose
Interventions
Other: Saline placebo
Registration Number
NCT04905901
Lead Sponsor
Assiut University
Brief Summary

The results of several recent studies on endoscopic sinus surgery through topical administration of tranexamic acid are encouraging in terms of the efficacy of tranexamic acid for intraoperative bleeding and other pathological conditions.The purpose of this study is to analyze the efficacy of nebulized tranexamic acid to improve the surgeon and patient experiences of sinus surgery and know the effective and safe dose of nebulized tranexamic acid.

Detailed Description

A written informed consent will be taken from the patients.The study involved adults of either sexes (age 18-65 years) of ASA I-II who will be listed for elective functional endoscopic sinus surgery (FESS) under general anesthesia, with normal accepted coagulation profile and hematocrit value ≥30 %. Excluded from the study patients with chronic renal failure, liver cirrhosis, bleeding disorders, current anticoagulant therapy, pregnancy or breastfeeding, impaired color vision, severe vascular ischemia, history of venous thrombosis, pulmonary embolism, long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery, a hemoglobin (HB) concentration \<10 mg/dl or allergy to TXA.

Randomization: A random number sequence created by an internet website (http://www. random.org) will be used for patients' allocation. The random number sequence was retained in closed opaque envelopes released the day of the surgery by an independent physician not involved in the study. Patients will be assigned randomly to three groups (30 subjects each); saline placebo (Group S) and two different doses of preemptive nebulized tranexamic acid (Group T1) and (Group T2).To keep blinding, Group S will receive 2 sessions of nebulization each by 5 ml saline. Group T1 will receive one nebulization session 500 mg tranexamic acid (5 ml) and another one by 5 ml saline. Group T2 will receive 2 nebulization sessions each by 500 mg tranexamic acid (each by 5 ml)

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Either sexes (age 18-65 years) of ASA I-II who are listed for elective functional endoscopic sinus surgery (FESS) under general anesthesia
  • normal accepted coagulation profile and hematocrit value ≥30
Exclusion Criteria
  • chronic renal failure
  • liver cirrhosis
  • bleeding disorders
  • current anticoagulant therapy
  • pregnancy or breastfeeding
  • impaired color vision
  • severe vascular ischemia
  • history of venous thrombosis, pulmonary embolism
  • long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery
  • hemoglobin (HB) concentration <10 mg/dl _allergy to TXA.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saline placeboSaline placeboNormal saline nebulization 15 minutes before operation
Tranexamic acid 500 mgTranexamic acidNebulized tranexamic acid 500 mg 15 minutes before operation
Tranexamic acid 1gmTranexamic acidNebulized tranexamic acid 1 gm 15 minutes before operation
Primary Outcome Measures
NameTimeMethod
the Modena Bleeding Score (MBS) assessing surgical fieldAfter anesthesia induction to 60 minute

1= No bleeding, 2=Bleeding easily controlled by suctioning, washing or packing without any significant modification or slowing of surgical procedure, 3=Bleeding slowing surgical procedure, 4=Most of the maneuvers dedicated to bleeding control and 5=Bleeding that prevents every surgical procedure except those dedicated to bleeding control

Secondary Outcome Measures
NameTimeMethod
Anesthetic consumptionAnesthesia duration

Extra doses of fentanyl and propofol and sevoflurane\>2

MBPIntraoperative duration

Mean blood pressure mmHg

Postoperative complicationsAfter operation to 24 hour

Recording any adverse effects to TXA e.g.nausea, vomiting and any visual disturbances

HRIntraoperative duration

Heart rate beat/min

Trial Locations

Locations (1)

Assuit

🇪🇬

Assiut, Assuit, Egypt

© Copyright 2025. All Rights Reserved by MedPath